Neonatal nosocomial Gram-negative rod bacteremia (GNR-b) is considered ominous.
INTRODUCTION
Nosocomial bacteremia is a leading cause of mortality in very low birthweight (VLBW: <1500 g birthweight) infants. [1] [2] [3] [4] [5] [6] [7] [8] Compared to bacteremia with Gram-positive organisms, Gram-negative rod bacteremia (GNR-b), particularly bacteremia with Pseudomonas, has been shown to be associated with increased mortality. 5, 6 Most of the published research in neonatal nosocomial bacteremia has been limited to single center studies 1, 3, 4 or to major academic medical center collaborative studies. 5, 6 There are increasing incentives to study antibiotics and adjunctive therapies for sepsis in adolescents, children, toddlers, infants, and neonates. This will result in an increase in the evaluation of these products in Neonatal Intensive Care Units (NICUs), and these trials will need to be designed with reliable and relevant end points. Possible end points for interventional trials in GNR-b in premature infants include mortality. We sought, therefore, to examine risk factors for mortality following GNR-b from a diverse group of NICUs.
Greater mortality following Pseudomonas bacteremia has been previously reported. 6 The development of immune competence in the premature neonate occurs over the first several weeks to months of life. [9] [10] [11] [12] We therefore hypothesized that mortality following GNR-b would be most strongly associated with postconception age at infection and infection with Pseudomonas.
METHODS
Neonates eligible for inclusion in the study were discharged from 100 NICUs managed by Pediatrix Medical Group, Inc. These infants were born between September 16, 1996 and December 27, 2001 , were r1250 g birthweight, and survived until at least the third day of life. The pediatrix group cared for 13,468 infants born r1250 g birthweight; 6172 of these infants had a blood culture after day of life 3. From a database derived from a computerassisted tool that generates clinical progress notes on neonates cared for by the Pediatrix Group, 13 we extracted data on birthweight, estimated gestational age (EGA), gender, and race. We were also able to collect the following clinical data at the time of blood culture for all reported blood cultures obtained from each patient after day of life 3 until death or discharge: need for mechanical ventilation, corticosteroids (although specification of the use of dexamethasone or hydrocortisone was not in the deidentified data used for this analysis), central vascular access, and use of intralipids.
Blood culture acquisition and processing was variable. Site of blood culture acquisition (central catheter, peripheral vessel) was not standardized within or between NICUs. There was not a standardized protocol for processing blood cultures between NICUs other than to follow NCCLS guidelines. 14 The unit of observation for this analysis was the neonate. The outcome of interest was mortality following the first positive blood culture for a GNR. Birthweight and EGA were evaluated as both categorical and continuous variables; we also evaluated race, gender, and clinical condition at the time of culture including: mechanical ventilation, antibiotics, intralipids, and vascular access as categorical variables.
Blood isolate was a categorical variable. Of the 6172 infants, 437 had GNR-b where the organism was speciated and only one organism was isolated from the blood. For 50 blood cultures, multiple organisms were grown or the organism was not speciated (identified only by Gram stain).
For the regression analysis, we used logistic regression and derived dummy variables for each genus (Acinetobacter, Citrobacter, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Serratia, and Stenotrophomonas) and used a positive blood culture with Escherichia (E. coli) as the reference category. In the initial logistic regression models, we assessed the relationship between genus and in-hospital mortality using eight categories of genus with E. coli as the referent. We then evaluated the effect of adding potentially confounding variables (i.e. gender) to the model that included death as the outcome and organism and confounding variables as independent variables. As several organisms each contributed 2% or less of the study population (Acinetobacter, Citrobacter, and Stenotrophomonas), we conducted the analysis with and without these three organisms. The analyses were similar, and we report the models with the limited number of organisms.
The first positive blood isolate for GNR-b was chosen so as to give the clinician the most precise estimates of risk factors at the time of initial presentation. The results were unchanged in a duplicate analysis that used last blood culture prior to death.
In the multivariable regression, we evaluated age at time of blood culture in days. We categorized age into three groups F day of life (DOL) <14, DOL 14 to 28, and DOL >28. In the analysis of the relationship between age and mortality, we were concerned about the influence of our open cohort design and competing risks. Following GNR-b, subsequent neonatal mortality might be due to the GNR-b or it might be due to competing risks such as morbidities associated with extreme prematurity. For example, a neonate born at 24-weeks EGA who has a blood culture on DOL 4 likely has different competing risks than a 24-week EGA neonate who has a blood culture drawn on DOL 120.
Owing to concerns that the relationship between age and mortality that we observed was related more to competing risks than risk of mortality due to GNR-b, we repeated the analysis with 3-, 7-, and 30-day mortality, thereby shortening the time interval from positive culture to potential unfavorable outcome due to GNR-b. The results were similar and the models presented focus on crude mortality. We also evaluated age as a function of postconception age (estimated gestational age þ week of age ¼ PCA). The association between PCA and mortality was stronger than either the association between EGA and mortality, or the association between DOL and mortality. The analysis is thus focused on the relationship between PCA and mortality in the final multivariable model.
All variables in the final multivariable model were further analyzed with the use of interaction terms. In order to present a parsimonious model, we decided a priori to retain interaction terms in the final model if p<0.05.
We conducted the analysis using SAS 8.02, (SAS Institute, Cary, NC) and STATA 6.0/7.0 (Stata Corporation, College Station, TX); reported p-values are two-tailed and we used Wald 95% confidence intervals (CI). Permission to conduct the analysis without written informed consent was provided by the Duke University Institutional Review Board because the analysis was completed on data without identifiers. As the data were analyzed without identifiers, we could not evaluate site-specific effects. Specifically, in order to complete the study without informed consent, we could not analyze the data stratified by site.
RESULTS
The source population consisted of 6172 infants with birthweight r1250 g. Of these, 437 (7%) developed GNR-b with a single organism. In Table 1 , we present the demographics of the patients in this cohort, clinical presentation, and the organisms isolated from the blood.
Neonates who developed GNR-b due to Pseudomonas were at higher risk of subsequent mortality than those whose developed GNR-b with other organisms (Figure 1) .
In logistic regression modeling (Table 2) , we separated the GNR into five groups: E. coli, Enterobacter, Serratia, Klebsiella, and Pseudomonas. We then conducted modeling with mortality as the outcome; the predictor variables were organism group (E. coli was referent), patient demographics, and clinical presentation. In the bivariable (unadjusted) analysis (Table 2) , organism isolated was associated with mortality. Neonates who had a positive blood culture for Pseudomonas were at greater odds of mortality than were neonates who had GNR-b with E. coli. Odds of subsequent mortality were not substantively different between enteric GNR-b.
Unadjusted analysis also indicated that younger DOL, younger EGA, and younger PCA were each associated with increased odds of subsequent mortality. The strongest association was between PCA and mortality. We evaluated age (DOL, EGA, and PCA) of the neonate when the blood culture was drawn in several models. First, we evaluated these as continuous variables. Older infants were at reduced odds of subsequent mortality when age was a continuous Benjamin et al. Neonatal Nosocomial Gram-negative Rod Bacteremia variable. As categorical variables often provide for a more meaningful interpretation, we also evaluated these categorical variables (older age was the referent in these analyses) and those results are presented in Tables 2 and 3 . We related empirical use of antibiotics at the time of blood culture to mortality. In the unadjusted analysis, neonates who received vancomycin or a third-generation cephalosporin as empirical therapy (when the blood culture was drawn or in the week prior to blood culture being drawn) were at no less odds of mortality than neonates who did not receive these products.
In order to control for confounding by EGA and other important clinical features, we conducted multivariable analysis (adjusted analysis; Table 3 ). Organism isolated from the blood (specifically Pseudomonas and Serratia), mechanical ventilation, children whose race was nonwhite nonblack, and PCA when the blood culture was obtained were the strongest risk factors to predict mortality. In the analysis of PCA as a risk factor for mortality, neonates >34 weeks PCA when the blood culture was obtained were the reference category. Comparatively, neonates PCA <26 weeks were more likely to die prior to discharge (OR ¼ 9.21; 95% CI ¼ 2.79, 30.44); higher mortality was also seen in neonates 26-28 weeks PCA (OR ¼ 3.94; 95% CI ¼ 1.29, 12.03). Figure 1 . A 100-day survival following first blood culture from 437 neonates with GNR-b. The Kaplan-Meier graph is stratified by blood culture result: E. coli, Enterobacter, Klebsiella, Serratia, and Pseudomonas.
In the adjusted analysis, we evaluated the relationship between the receipt of empirical extended spectrum of activity antibiotics (vancomycin, third-generation cephalosporin, and carbapenems) when the blood culture was obtained to odds of subsequent mortality. Empirical use of these antibiotics was not associated with subsequent mortality. Also not associated with mortality in the multivariable analysis was gender, presence of a central catheter, receipt of intralipids, steroids, or birthweight.
As this was an open cohort (days of follow-up after GNR-b was variable), we suspected that our estimates of increased odds of death with younger age might be biased. So we repeated the analysis examining PCA as an independent variable predicting mortality several models. The first model is presented in Table 3 and in that model, death prior to discharge is the outcome Table 2 continued variable. We then repeated the analysis with 30-, 7-, and 3-day mortality following acquisition of the blood culture. Specifically, in the 3-day analysis, neonates were considered to have ''survived'' their episode of GNR-b if they were alive 3 days after the first positive blood culture. The multivariable results for these models were similar to what we present in Table 3 .
DISCUSSION
Nosocomial GNR-b is a leading cause of mortality in premature infants. 5, 6 We sought to describe the incidence of documented GNR-b in a cohort of premature neonates from a diverse group of NICUs, and to evaluate risk factors for subsequent mortality.
We found that the mortality for the common enteric GNR (E. coli, Enterobacter, Klebsiella, and Serratia) was substantial, ranging from 10 to 20%, but the mortality for those infants bacteremic for Pseudomonas was higher at 34%. In the multivariable modeling, presence of Pseudomonas or Serratia was associated with higher mortality than bacteremia with E. coli. In the multivariable modeling, we used Escherichia as the GNR reference category for several reasons: (1) it is a common cause of both early-and late-onset neonatal bacteremia, (2) historically it has been a common cause of neonatal GNR bacteremia, and (3) it was one of the most common organisms in this analysis.
We also found that younger age was consistently associated with mortality. Although this association was seen when we evaluated DOL, EGA, and PCA, the strongest association was related to PCA. The newborn infant as an immune-compromised host has been well recognized F aspects of compromise include antibody production against polysaccharide antigens, T-cell naiveté, reduced bone marrow reserve, complement function, and neutrophil deficiencies in bactericidal permeability increasing protein. [9] [10] [11] [12] This compromise and subsequent development of the immune system may relate to our observation that younger PCA was so closely linked to subsequent mortality in this cohort.
We also found that infants who were nonblack/nonwhite race had higher mortality. Most of these infants (>80%) were Hispanic; approximately 10% were Asian and approximately 10% were Native American. The relationship between race and mortality may be related to NICU site-specific differences; however, this relationship could not be assessed due to the anonymized nature of these data. Previous investigators have reported race to be a risk factor in neonatal sepsis; likewise, host genetic risk factors have been related to outcome in patients with sepsis. 15, 16 Interestingly, we also found that the use of extended spectrum antibiotics (third-generation cephalosporins, and carbapenems) with broad activity against GNR was common practice in Pediatrix NICUs, but was not associated with substantially different odds of mortality in the bivariable or multivariable analysis. This finding should be interpreted with caution. Relationship in standard logistic regression analysis between empirical antibiotic use and subsequent mortality is very difficult to interpret, and this question is best addressed in a prospective trial.
It is noteworthy, however, that our results are consistent with those reported by previous investigators. Karlowicz et al. 4 reported that antibiotic choice did not influence mortality in a 10-year analysis of data at one institution. In that study, the authors compared the use of vancomycin and a third-generation cephalosporin to use of oxacillin and an aminoglycoside and found no relationship between choice of antibiotic regimen and mortality.
The data we present have several substantial limitations. First, although the data were collected prospectively, no power analysis was completed prior to the start of data collection and the data were collected primarily for clinical documentation rather than clinical research. Data collection was therefore not designed with the specific question we addressed and this study suffers from many of the limitations of a retrospective study. Further, the data could not be analyzed at the individual site level; all site identification was removed prior to analysis in order to make the data anonymized and thus eligible for analysis without obtaining informed consent. We could not therefore analyze the effects of any potential or confirmed ''outbreaks'' of GNR bacteremia in this study.
The data we present have several strengths and most of them relate to the diversity of NICUs involved in the collection of data (see Acknowledgments), the large sample size, and the ability of future investigators to use these data as a platform to design future clinical trials. For example:
(1) Our data (and data presented by others 4 ) may be used as a layer of evidence that a randomized trial of empirical antimicrobial therapy is warranted.
(2) These data are especially relevant to future study design in randomized interventional trials of the treatment of GNR-b. We had access to a source population of 6172 infants with birthweight <1250 g. Only 437 developed GNR-b and there were 71 deaths. A noninferiority trial of a new antibiotic with activity against GNR organisms whereby inclusion is based on Gram-stain results can use these results to plan a trial with mortality as the end point.
(3) These data are also relevant to GNR-b prevention with adjunctive therapies such as monoclonal or polyclonal antibodies. Although results from well-designed trials using IVIG to prevent neonatal nosocomial bacteremia have been mixed, 17, 18 such trials are now underway for products that specifically prevent Grampositive bacteremia.
